News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

News|Videos|October 18, 2023

Why You Should Attend the 2023 Psychiatric Times World CME Conference

Author(s)John J. Miller, MD

Our Editor in Chief explains why you should attend our conference!

John J. Miller, MD, the Editor in Chief of Psychiatric Times, is excited for our virtual conference. Here's why you should be too!

You can register here.

Dr Miller is Medical Director, Brain Health, Exeter, New Hampshire; Editor in Chief, Psychiatric Times®; Staff Psychiatrist, Seacoast Mental Health Center, Exeter; Consulting Psychiatrist, Exeter Hospital, Exeter; Consulting Psychiatrist, Insight Meditation Society, Barre, Massachusetts.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

2026 Conference Insights: ASCP

ByHeidi Anne Duerr, MPH,Leah Kuntz,Jessica Walters

July 23rd 2026

data

2026 Conference Insights: APA

ByJessica Walters,Leah Kuntz

July 23rd 2026

data

2026 Conference Insights: SIRS

ByJessica Walters

July 23rd 2026

Nyaaka/Adobe Stock

What's Next for Psychedelics in Psychiatry? COMP360 and Beyond

ByGustavo Alva, MD, DFAPA,Jessica Walters

July 16th 2026

Vagus Nerve Stimulation in Difficult-to-Treat Depression: When Does It Work Best?

ByGustavo Alva, MD, DFAPA

July 14th 2026

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Trending on Psychiatric Times

Centanafadine's Route to FDA Review: A Clinical Path of the ADHD Medication

Underdiagnosed and Undertreated: Verena Ramirez Campos, MD, on Tardive Dyskinesia Care

Podcast: The Power of the Placebo Effect. A Conversation With Walter A. Brown, MD

Earn CME Credit With Psychiatric Times: Don’t Miss These Articles